Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
There are three GLP-1 FDA decisions expected in early-mid 2026 Eli Lillys Mounjaro with a new indication to reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM Eli Lillys oral once-daily orforglipron for weight loss Novo Nordisks higher dose (7.2 mg) injectable once-weekly Wegovy for weight loss Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
Federal gastrointestinal injury claims involving Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, and related GLP-1 medications are centralized in MDL No
By aligning your injection schedule with your lifestylewhether that means prioritizing weekend recovery or weekday focusyou set yourself up for a sustainable and successful journey
GLP-1s are considered safe and unprecedentedly effective aids to weight loss and associated health risks, such as type 2 diabetes
